MedWatch

Analyst: Demant's Oticon More generates strong VA figures

Demant's market share of the public US sales channel VA rose to 14.74 percent in May compared to 9.21 percent the month before, which a DNB analyst calls a strong development.

Photo: Thomas Borberg/Politiken/Ritzau Scanpix

Since launching Oticon More on the public US sales channel Veterans Affairs (VA) in May, Demant has gained large market shares for hearing aids.

DNB Equity Analyst Rune Majlund Dahl calls this a "very strong" development.

Read the whole article

Get 14 days free access.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Pfizer upgrades guidance for sales of covid-19 vaccine

The US pharmaceutical company Pfizer now predicts sales of its coronavirus vaccines will total USD 33.5bn this year. The previous estimate was UDS 26bn. Meanwhile, the company has revealed the guidance for its annual revenue.

Further reading

Related articles

Trial banner

Latest news

See all jobs